论文部分内容阅读
目的:探讨双氯芬酸钠栓和索利那新治疗TURP术后OAB的临床疗效及预防性用药的必要性。方法:采取随机区组单盲的临床试验设计,将入选患者随机分为预防用药组和观察用药组。预防性用药组分别别使用双氯芬酸钠栓、索利那新片单药处理及两种药物联合处理,观察用药组在出现症状后按照预防性用药组的相同方法给药。结果:观察用药组中,双氯芬酸钠栓治疗的完全缓解率为50%,索利那新为81.8%,联合用药为90.5%,显著高于双氯芬酸钠栓(P<0.05),各组不良反应的发生情况比较无显著性差异(P>0.05)。预防用药组中,索利那新、双氯芬酸钠栓及联合用药分别可使TURP术后OAB的发生率降低45.0%、50.9%、53.8%.,三组之间比较无统计学差异(P>0.05),且三组不良反应的发生情况比较无显著性差异(P>0.05)。结论:双氯芬酸钠栓和索利那新治疗TURP术后OAB均安全有效,联合用药效果更佳,且预防性用药可以显著降低TURP术后OAB症状的发生率。
Objective: To investigate the clinical efficacy of diclofenac sodium suppository and solifenacin in the treatment of OAB after TURP and the necessity of preventive medication. Methods: Randomized block single-blind clinical trial design, the selected patients were randomly divided into prophylaxis group and observation drug group. Preventive medication components were not to use diclofenac sodium suppository, solifenacine tablets treatment and two drugs combined treatment group was observed after the onset of symptoms in accordance with the prophylactic drug group administered in the same manner. Results: In the observation group, the complete remission rate of diclofenac sodium suppository was 50%, the rate of solifenacin was 81.8%, the combination regimen was 90.5%, which was significantly higher than that of diclofenac sodium suppository (P <0.05) There was no significant difference (P> 0.05). In prophylaxis group, the incidence of OAB after TURP was reduced by 45.0%, 50.9% and 53.8%, respectively, with no significant difference between the three groups (P> 0.05) ), And the incidence of adverse reactions in the three groups showed no significant difference (P> 0.05). Conclusion: Both diclofenac sodium suppository and solifenacin are safe and effective in the treatment of OAB after TURP, and the combination therapy is better. Prophylactic treatment can significantly reduce the incidence of OAB symptoms after TURP.